CA3201512A1 - Methods of improving the pharmacokinetics of migalastat - Google Patents

Methods of improving the pharmacokinetics of migalastat Download PDF

Info

Publication number
CA3201512A1
CA3201512A1 CA3201512A CA3201512A CA3201512A1 CA 3201512 A1 CA3201512 A1 CA 3201512A1 CA 3201512 A CA3201512 A CA 3201512A CA 3201512 A CA3201512 A CA 3201512A CA 3201512 A1 CA3201512 A1 CA 3201512A1
Authority
CA
Canada
Prior art keywords
migalastat
salt
patient
caffeine
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3201512A
Other languages
English (en)
French (fr)
Inventor
Franklin Johnson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amicus Therapeutics Inc
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of CA3201512A1 publication Critical patent/CA3201512A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3201512A 2022-12-13 2023-05-31 Methods of improving the pharmacokinetics of migalastat Pending CA3201512A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263432235P 2022-12-13 2022-12-13
US63/432,235 2022-12-13
US18/315,928 US20240197706A1 (en) 2022-12-13 2023-05-11 Methods of improving the pharmacokinetics of migalastat
US18/315,928 2023-05-11

Publications (1)

Publication Number Publication Date
CA3201512A1 true CA3201512A1 (en) 2024-06-13

Family

ID=86646511

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3201512A Pending CA3201512A1 (en) 2022-12-13 2023-05-31 Methods of improving the pharmacokinetics of migalastat

Country Status (13)

Country Link
US (1) US20240197706A1 (enExample)
EP (1) EP4385509B1 (enExample)
JP (1) JP7757345B2 (enExample)
KR (1) KR20240094973A (enExample)
AU (1) AU2023396459A1 (enExample)
CA (1) CA3201512A1 (enExample)
CL (1) CL2025001743A1 (enExample)
CO (1) CO2025009079A2 (enExample)
DE (1) DE202023003007U1 (enExample)
IL (1) IL321404A (enExample)
MX (1) MX2025006897A (enExample)
TW (1) TW202423436A (enExample)
WO (1) WO2024129220A1 (enExample)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
EP2142197A4 (en) 2007-03-30 2010-11-10 Amicus Therapeutics Inc PROCESS FOR THE TREATMENT OF FABRY DISEASE USING PHARMACOLOGICAL CHAPERONS
US9999618B2 (en) * 2007-04-26 2018-06-19 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
LT3470077T (lt) 2008-02-12 2021-02-25 Amicus Therapeutics, Inc. Atsako į ligų gydymą farmakologiniu šaperonu prognozavimo būdas
CN103974619B (zh) * 2011-03-11 2017-02-15 阿米库斯治疗学公司 治疗法布里病的给药方案
JP2024542023A (ja) * 2021-11-03 2024-11-13 サンガモ セラピューティクス，インコーポレイテッド ファブリー病の治療のためのウイルスベクター構築物の使用方法

Also Published As

Publication number Publication date
JP2024084670A (ja) 2024-06-25
JP7757345B2 (ja) 2025-10-21
CL2025001743A1 (es) 2025-10-03
KR20240094973A (ko) 2024-06-25
EP4385509B1 (en) 2025-09-03
IL321404A (en) 2025-08-01
DE202023003007U1 (de) 2025-07-21
WO2024129220A1 (en) 2024-06-20
MX2025006897A (es) 2025-07-01
TW202423436A (zh) 2024-06-16
EP4385509A1 (en) 2024-06-19
US20240197706A1 (en) 2024-06-20
AU2023396459A1 (en) 2025-06-26
CO2025009079A2 (es) 2025-09-29

Similar Documents

Publication Publication Date Title
US11278537B2 (en) Methods of treating Fabry patients having renal impairment
US20220313670A1 (en) Methods Of Treating Fabry Disease In Patients Having Renal Impairment
US20210251972A1 (en) Methods Of Treating Fabry Disease
US20240293387A1 (en) Methods of Treating Fabry Disease in Pediatric Patients
EP4385509B1 (en) Migalastat dosage regimen having improved pharmacokinetics
HK40110919A (en) Migalastat formulations having improved pharmacokinetics
CN118488839A (zh) 改善米加司他的药代动力学的方法